DRUG · Mapped RxNorm record
Linagliptin
Normalized identity: linagliptin View linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
Rotation for Optimal Targeting of Albuminuria and Treatment Evaluation (ROTATE-2)
NCT03504566
Study summary
ClinicalTrials.govRotation for Optimal Targeting of Albuminuria and Treatment Evaluation (ROTATE-2)
Design: INTERVENTIONAL · Status: WITHDRAWN · Phase: PHASE4
Loading study purpose, treatment groups and outcomes…
View the complete registry record, eligibility and contacts at ClinicalTrials.gov
Drugs and interventions used in this trial
4 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
Empagliflozin
Normalized identity: empagliflozin View linked drug · Find medicine records ·
Find other trials using this name
DRUG · Mapped RxNorm record
Telmisartan
Normalized identity: telmisartan View linked drug · Find medicine records ·
Find other trials using this name
DRUG · Unmapped registry intervention
Sulodexide
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Advertisement
Conditions
Diabetic Nephropathy Type 2unresolved
Interventions
LinagliptinDRUG · verified · RxNorm: linagliptin
EmpagliflozinDRUG · verified · RxNorm: empagliflozin
TelmisartanDRUG · verified · RxNorm: telmisartan
SulodexideDRUG
Sponsors & collaborators
Steno Diabetes Center Copenhagenlead sponsor
University Medical Center Groningencollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03504566 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.